Meet The CEOs

Martin Filz, CEO at Pureprofile (ASX: PPL) discusses the company’s plans to grow revenues from its data acquisition, analytics and insights platform, the surge in demand for data analytics and how Pureprofile’s platform is positioned to meet that demand. Pureprofile (ASX: PPL) connects businesses with empowered consumers across the world by connecting, understanding and engaging them through direct-to-consumer technology platforms. Any advice contained within this presentation is general advice and does not consider your objectives, financial situation or needs, and you should consider whether it’s appropriate for you. The information we are giving you is for educational purposes only. Accurate time of recording, 3 March 2021, 12pm AEDT.

Auctus Investment Group (ASX: AVC) Managing Director Campbell McComb provides insights into the company's strong position within the private equities, infrastructure and private real estate sectors, its strategic offershore partnerships and global market presence. Auctus Investment Group (ASX: AVC) is a global investment manager with approximately A$250M Assets Under Management, focusing on opportunities across private equity, infrastructure and private real estate. Any advice contained within this presentation is general advice and does not consider your objectives, financial situation or needs, and you should consider whether it’s appropriate for you. The information we are giving you is for educational purposes only. Accurate time of recording, 3 March 2021, 12pm AEDT.

PointsBet Holdings (ASX: PBH) CFO Andrew Mellor discusses the company's exciting growth in the US and continued momentum in the Australian markets, as well as its transformational 5-year media partnership with NBC Universal and what it means for the company. PointsBet (ASX: PBH) are corporate bookmakers with operations in Australia and the United States, who have developed a scalable cloud-based wagering platform through which they offer clients innovative sports and racing wagering products. Any advice contained within this presentation is general advice and does not consider your objectives, financial situation or needs, and you should consider whether it’s appropriate for you. The information we are giving you is for educational purposes only. Accurate time of recording, 3 March 2021, 12pm AEDT.

Marenica Energy (ASX: MEY) Managing Director Murray Hill discusses the company's planned exploration activity for the next 12 months across the company’s giant palaeochannels in Namibia, and how their patented U-pgrade™ uranium beneficiation process gives Marenica a clear sustainable advantage and a faster, low-cost pathway to production. Marenica Energy Limited (ASX: MEY) is an ASX listed exploration company with a three-pronged strategy for advancing the Company: Explore its own projects; Acquire projects in which U-pgrade™ can add value; and Apply U-pgrade™ to third party projects. Any advice contained within this presentation is general advice and does not consider your objectives, financial situation or needs, and you should consider whether it’s appropriate for you. The information we are giving you is for educational purposes only. Accurate time of recording, 17 February 2021, 12pm AEDT.

Emyria Limited (ASX: EMD) CEO Dr Michael Winlo discusses why the company is well positioned to rapidly and repeatedly develop new treatments as well as its key partnerships, recent achievements and strategic plans for the upcoming year. Emyria Limited (ASX: EMD) is a data-backed, drug development company. Emyria’s Treatments target unmet needs and are focused on obtaining approval from major global regulators. Any advice contained within this presentation is general advice and does not consider your objectives, financial situation or needs, and you should consider whether it’s appropriate for you. The information we are giving you is for educational purposes only. Accurate time of recording, 17 February 2021, 12pm AEDT.

Nexion Group (ASX: NNG) CEO Paul Glass provides insights into the company's unique offering to the rapidly evolving technology industry of global companies, and how Nexion came to the point of publicly listing and what this means for the future of the company. Nexion Group (ASX: NNG) is a leading Asia-Pacific headquartered global cloud and enterprise technology solutions provider. Any advice contained within this presentation is general advice and does not consider your objectives, financial situation or needs, and you should consider whether it’s appropriate for you. The information we are giving you is for educational purposes only. Accurate time of recording, 17 February 2021, 12pm AEDT.

CEO Julian Challingsworth discusses why Tesserent (ASX: TNT) is Australia's leading ASX-listed cybersecurity firm and how the company hs increased its footprint substantially over the past year through a number of acquisitions. Tesserent (ASX: TNT) is Australia’s largest ASX listed cybersecurity provider, is on track to deliver on our strategy to provide clients with a full suite of cybersecurity services: Cyber 360. Any advice contained within this presentation is general advice and does not consider your objectives, financial situation or needs, and you should consider whether it’s appropriate for you. The information we are giving you is for educational purposes only. Accurate time of recording, 21 October 2020 at 12pm AEDT.

Managing Director Glenn Smith provides an overview of TALi Digital's (ASX: TD1) world first personalised digital test and treatment platform for early childhood attention. During the session, Glenn discusses the company's global market presence, unique market advantage, and commercial roll out across Australia, India, the US and UK. TALi Digital (ASX: TD1) is an Australian Medical Technology Company seeking to improve attention in early childhood through its breakthrough TALi platform. Any advice contained within this presentation is general advice and does not consider your objectives, financial situation or needs, and you should consider whether it’s appropriate for you. The information we are giving you is for educational purposes only. Accurate time of recording, 21 October 2020 at 12pm AEDT.

CEO Dr John Lambert discusses the Amplia Therapeutics' (ASX: ATX) exciting progress in developing new experimental drugs to treat cancer and fibrosis, an update on the AMP945 clinical trial and the company's collaboration with the Garvan Institute. Amplia Therapeutics (ASX: ATX) is an Australian pharmaceutical company developing new drugs for cancer and fibrosis. Any advice contained within this presentation is general advice and does not consider your objectives, financial situation or needs, and you should consider whether it’s appropriate for you. The information we are giving you is for educational purposes only. Accurate time of recording, 21 October 2020 at 12pm AEDT.

Managing Director Murray Hill provides insights into the drivers seeing uranium demand continue to outstrip supply, the company's significant uranium discoveries in the Namibia exploration area, and an overview of their U-pgrade™ patented process developed with CSIRO. Marenica Energy (ASX: MEY) is an exploration company with a three-pronged strategy for advancing the Company: Explore its own projects; Acquire projects in which U-pgrade™ can add value; and Apply U-pgrade™ to third party projects. Any advice contained within this presentation is general advice and does not consider your objectives, financial situation or needs, and you should consider whether it’s appropriate for you. The information we are giving you is for educational purposes only. Accurate time of recording, 7 October 2020 at 12pm AEDT.